Connected With Latham

97 Afleveringen

1. Episode 57 – Drug Pricing: What Trends Emerged from the 2023 Medicaid Drug Rebate Program Summit?

   Gepubliceerd: 20-10-2023
2. Episode 56 – M&A Views: Avoiding Buyer’s Remorse in M&A Deals

   Gepubliceerd: 27-9-2023
3. Episode 55 – Insurtech: What Should Startups Do After Receiving FCA Authorization?

   Gepubliceerd: 21-9-2023
4. Episode 54 – Drug Pricing: Focus on Best Price — CMS Proposed Rule, Inflation Reduction Act

   Gepubliceerd: 15-9-2023
5. Episode 53 – Energy & Infrastructure: Can Sustainable Finance Fuel the Energy Transition?

   Gepubliceerd: 30-8-2023
6. Episode 52 – Drug Pricing: Could a Single Reference Price Apply Across a Therapeutic Class?

   Gepubliceerd: 21-8-2023
7. Episode 51 – Drug Pricing: Final IRA Price Negotiation Guidance – How CMS Addressed the Part D/B Problem

   Gepubliceerd: 31-7-2023
8. Episode 50 – PE Views: Under New Reforms, Is the Customer Always Right?

   Gepubliceerd: 14-7-2023
9. Episode 49 – PE Views: Will Greenwashing Rain on the UK PE Parade?

   Gepubliceerd: 20-6-2023
10. Episode 48 – M&A Views: Will UK-Bound M&A Need to Come to US Terms?

    Gepubliceerd: 27-4-2023
11. Episode 47 – Real Estate Realities in Europe: Expensive Money and the Power of Private Equity

    Gepubliceerd: 17-4-2023
12. Episode 46 – PE Views: PE Must Strike the Right Balance With Unions

    Gepubliceerd: 31-3-2023
13. Episode 45 – Will Insurtech Reach New Heights in 2023?

    Gepubliceerd: 8-3-2023
14. Episode 44 – PE Views: Private Equity Looks to Share-Based Schemes to Incentivise Non-Managerial Staff

    Gepubliceerd: 20-1-2023
15. Episode 43 – Energy & Infrastructure: The Drivers and Opportunities of Asia’s Digital Infrastructure Boom

    Gepubliceerd: 1-11-2022
16. Episode 42 – PE Views: Has Rethinking Cannabis Sparked PE Interest?

    Gepubliceerd: 11-7-2022
17. Episode 41 – PE Views: Why Do Music Deals Sound So Attractive to PE?

    Gepubliceerd: 9-6-2022
18. Episode 40 – PE Views: Could PE Benefit From the Universal Adoption of “Super Senior” RCFs in Leveraged Financings?

    Gepubliceerd: 28-4-2022
19. Episode 39 – New FDA Commissioner Dr. Califf: What His Appointment Means for the Regulated Industry and What to Watch for in 2022

    Gepubliceerd: 15-2-2022
20. Episode 38 – PE Views: How are ESG Regulatory Reforms and Investor Focus Shaping the Market?

    Gepubliceerd: 14-2-2022